http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103864819-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D501-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D501-46 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-12 |
| filingDate | 2014-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103864819-B |
| titleOfInvention | A kind of ceftazidime compound and pharmaceutical composition thereof |
| abstract | The present invention relates to a kind of ceftazidime compound and pharmaceutical composition thereof.The structural formula of described ceftazidime compound is as shown in formula I, and this compound powder X-ray diffraction algoscopy measures, and the X-ray powder diffraction pattern represented with the 2 θ ± 0.2 ° angles of diffraction is as shown in Figure 1.This compound not only has preferable heat stability, and has extraordinary mobility, and is tested by pharmacokinetics and surprisingly find, the ceftazidime compound of the present invention has preferable bioavailability. |
| priorityDate | 2014-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.